Google
Trusted Resources: News & Events
Latest announcements and gatherings
Imara’s IMR-687 for SCD Receives FDA Rare Pediatric Disease Designation
The U.S. Food and Drug Administration (FDA) granted rare pediatric disease designation to IMR-687, Imara’s drug candidate for the treatment of sickle cell disease (SCD). The investigational therapy has also been granted orphan drug status by the FDA.
Rare pediatric disease designation is granted to drugs that show promise for rare and serious or life-threatening diseases in U.S. patients, primarily age 18 years or younger. The designation provides incentives to advance the development of rare disease drugs, including access to the FDA’s expedited review and approval programs.
“People living with sickle cell disease have limited treatment options for its devastating effects,” James McArthur, PhD, Imara’s president and CEO, said in a news release. “The FDA’s decision reflects its commitment to working with innovators and the patient community toward advancing safe and effective treatments for children suffering from the rare and damaging pediatric manifestations of the disease.”
+myBinderRelated Content
-
Gene therapy targets sickle-cell diseaseElliott Vichinsky estimates that at leas...
-
Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional...Serial phlebotomy was performed on sixty...
-
The Influence of Perceived Racial Bias and Health-Related Stigma on Quality of Life Among Children With Sickle Cell ...Objectives: Individuals with sickle ce...
-
Step toward gene therapy for sickle cell diseaseA team of researchers at the Stanford Un...
-
bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene ...Patient treated with LentiGlobinTM drug ...
-
Miai & Ama Talk About Sickle Cell Diseasehttps://www.youtube.com/watch?v=7bUFGux-...
-
Voxelotor can Promote Long-Term Benefits in Teens, Adults With SCD, Latest Clinical Data ShowGlobal Blood Therapeutics’ lead therap...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
